Denali Therapeutics Inc. Common Stock (DNLI) is a publicly traded Healthcare sector company. As of May 21, 2026, DNLI trades at $18.52 with a market cap of $2.92B and a P/E ratio of -6.34. DNLI moved +3.92% today. Year to date, DNLI is +17.54%; over the trailing twelve months it is +31.77%. Its 52-week range spans $10.57 to $33.33. Analyst consensus is strong buy with an average price target of $35.91. Rallies surfaces DNLI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Denali Therapeutics Secures Fast Track for Hunter Syndrome Drug with PDUFA April 2026: Denali Therapeutics’ tividenofusp alfa for Hunter syndrome holds Fast Track, Breakthrough Therapy and Priority Medicines designations with an FDA PDUFA target date of April 2026. The therapy requires precise protein engineering and scaled biomanufacturing to cross the blood-brain barrier for consistent, large-scale production.
| Metric | Value |
|---|---|
| Price | $18.52 |
| Market Cap | $2.92B |
| P/E Ratio | -6.34 |
| EPS | $-2.97 |
| Dividend Yield | 0.00% |
| 52-Week High | $33.33 |
| 52-Week Low | $10.57 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-512.54M |
| Gross Margin | 0.00% |
14 analysts cover DNLI: 0 strong buy, 13 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.91.